Tag: dividend-stock
Cigna Group Stock Analysis: Buy or Sell? Valuation, Cash Flow & Margin
The Cigna Group (CI) is rated Hold as its durable cash generation offsets a post-divestiture earnings base that still needs to prove itself. The 9.0% FCF yield and 1.72x net debt to EBITDA support the stock, but margin improvement remains the key test.
Abbott Laboratories Stock Analysis: Valuation, Margins, Debt & Growth
Abbott Laboratories (ABT) is rated Hold as its diversified healthcare platform supports stability, but valuation and execution concerns cap near-term upside. Q1 2026 revenue and EBIT weakened sequentially, while debt tied to acquisition financing could pressure flexibility.
Verizon Stock Analysis: Buy or Sell? VZ Beta, Dividend & Valuation
Verizon Communications Inc. (VZ) earns a HOLD rating as its defensive cash flow and 7.5x EV/EBITDA valuation are offset by heavy leverage. Q1 2026 EBITDA rose 7.3% year over year, but $200.9B of debt keeps refinancing risk front and center.